🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,257 results for “First” Clear

  1. Combinations

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  2. Conventional Roux-en-Y Gastrojejunostomy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  3. Cyclophosphamide

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia, Pediatric

    phase 2 small molecule active

    1 trial

  4. Cyclosporine A

    The First People's Hospital of Lianyungang

    Bone Marrow Failure Disorders

    phase 2 small molecule active

    1 trial

  5. Cytokine-induced killer cells

    The First People's Hospital of Lianyungang

    Ovarian Carcinoma

    phase 2 mab active

    1 trial

  6. Cytokine-induced killer cells

    The First People's Hospital of Lianyungang

    Melanoma

    phase 2 mab active

    1 trial

  7. DA-EPOCH

    The First People's Hospital of Lianyungang

    NHL With Hemophagocytic Lymphohistiocytosis

    phase 2 small molecule active

    1 trial

  8. DC-CIK Immunotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 mab active

    1 trial

  9. DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)

    The First People's Hospital of Lianyungang

    Triple-Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  10. DMTs + taurine

    The First People's Hospital of Lianyungang

    Multiple Sclerosis (MS) Relapsing Remitting

    phase 2 small molecule active

    1 trial

  11. Dalpiciclib

    The First People's Hospital of Lianyungang

    Early Breast Cancer

    phase 2 small molecule active

    1 trial

  12. Darolutamide+ADT

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  13. Deep-sea fish oil

    The First People's Hospital of Lianyungang

    Radiation Toxicity

    phase 2 small molecule active

    1 trial

  14. Defosbarasertib, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    First-line patients with extensive disease small-cell lung cancer (SCLC)

    phase 2 small molecule active

    1 trial

  15. Dermatophagoides Farinae Drops Group 1

    The First People's Hospital of Lianyungang

    Atopic Dermatitis

    phase 2 mab completed

    1 trial

  16. Determine the ED50 and ED95 of esketamine

    The First People's Hospital of Lianyungang

    Intrauterine Polyp

    phase 2 small molecule active

    1 trial

  17. Dexamethasone

    The First People's Hospital of Lianyungang

    Precursor B-Cell Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  18. Disitamab Vedotin

    The First People's Hospital of Lianyungang

    HER2-positive Gastric Cancer

    phase 2 small molecule active

    1 trial

  19. Disitamab Vedotin (RC48)

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  20. Doxorubicin liposome

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  21. Dragon Boat Training

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  22. Drug-coated balloon angioplasty

    The First People's Hospital of Lianyungang

    Vertebral Artery Stenosis

    phase 2 other active

    1 trial

  23. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  24. EGFR Antibody

    The First People's Hospital of Lianyungang

    Nasopharyngeal Cancinoma (NPC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources